Health & Research Goals
Fat Burn Pro
Quema Grasa Pro
High-Performance Stack
Select a vial or the total
Primary Description
Ipamorelin reduces somatostatin (GHIH) to unlock natural GH production. Sermorelin stimulates pituitary GH release. Together they create clean GH elevation for lipolysis research without affecting cortisol or prolactin.
Demonstrated Effects
- Combined synergistic effect
- Maximized research outputs
- Pre-verified protocol
Proposed Mechanisms of Action
Combined Mechanism
Sermorelin is the native GHRH 1-29 NH2 fragment with a short half-life (10-20 minutes), producing natural, short-duration GH pulses that closely mimic endogenous secretion patterns. Ipamorelin activates the ghrelin receptor (GHS-R1a) via a separate pathway to amplify the GH peak without affecting cortisol or prolactin. The combination produces clean physiological GH pulses ideal for body fat reduction, lean mass preservation, and metabolic support.
Stack Compounds
Research Evidence & Clinical Data
Research Profile
A gentle GH secretagogue stack using Sermorelin and Ipamorelin for body composition optimization without the prolonged receptor stimulation associated with longer-acting GHRH analogs. Preferred for first-cycle users and those prioritizing natural pulse mimicry over maximum GH amplitude.
Safety Profile
Common Side Effects
- Transient flushing or headache immediately post-injection
- Mild water retention at higher doses
- Increased appetite (Ipamorelin ghrelin effect)
- Inject at bedtime to align with nocturnal GH pulsatility
Contraindications
- Active malignancy
- Pregnancy or breastfeeding
- Hypersensitivity to GHRH analogs
Analytical Quality Assurance
Research Protocols
Dosing Protocols
Combined Research Protocol: Quema Grasa Pro
Sub-QMonitoring & Risk Management
Compound Stack Monitoring
For stacks and blends, refer to the individual compound monographs for each included ingredient for specific monitoring guidelines.